Zevra Therapeutics is trading at $11.00, up 6.73%, after third-quarter 2026 revenue and reported earnings beat estimates. - Revenue rose 45% year over year to $37.8 million, ahead of estimates; MIPLYFFA contributed $34.0 million. - The results were released after the November 3 close, making them a company-specific catalyst for the November 4 move. Zevra discussed further MIPLYFFA expansion plans, including a planned supplemental FDA application in Q1 2027.